ESSA PharmaEPIX
EPIX
About: ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
Employees: 35
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 3 (+2) [Q1 2025]
2.65% less ownership
Funds ownership: 74.03% [Q4 2024] → 71.37% (-2.65%) [Q1 2025]
15% less capital invested
Capital invested by funds: $58.8M [Q4 2024] → $50.1M (-$8.76M) [Q1 2025]
22% less funds holding
Funds holding: 46 [Q4 2024] → 36 (-10) [Q1 2025]
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
Research analyst outlook
We haven’t received any recent analyst ratings for EPIX.
Financial journalist opinion
Neutral
PRNewsWire
1 month ago
ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025
Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025.
Neutral
Accesswire
2 months ago
Shareholders of ESSA Pharma Inc. Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138642&wire=1 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
2 months ago
ESSA Pharma Inc. Class Action: Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX
NEW YORK , March 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ESSA Pharma Inc. investors who were adversely affected by alleged securities fraud between December 12, 2023 and October 31, 2024.
Neutral
Business Wire
2 months ago
EPIX Deadline Today: Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of ESSA Pharma Inc. (NASDAQ: EPIX) securities between December 12, 2023 and October 31, 2024, inclusive (the “Class Period”). The lawsuit describes ESSA as a “clinical stage pharmaceutical company that focuses on the development of small molecular drugs for the treatment of prostate cancer.” For more information, submit a form, ema.
Neutral
Accesswire
2 months ago
ESSA Pharma Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138572&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
2 months ago
EPIX DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action - EPIX
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ:EPIX) between December 12, 2023 and October 31, 2024, inclusive (the "Class Period"), of the important March 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased ESSA Pharma Inc. securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
Accesswire
2 months ago
Investors who lost money on ESSA Pharma Inc.(EPIX) should contact Levi & Korsinsky about pending Class Action - EPIX
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138559&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
2 months ago
FINAL REMINDER EPIX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts ESSA Pharma Inc. Investors to Participate in the Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period").
Neutral
Accesswire
2 months ago
ESSA Pharma Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – EPIX
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138426&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
2 months ago
ESSA Pharma Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion
Investors can contact the law firm at no cost to learn more about recovering their losses
Charts implemented using Lightweight Charts™